CA2358438A1 - Methode antivirale utilisant des inhibiteurs de mek - Google Patents

Methode antivirale utilisant des inhibiteurs de mek Download PDF

Info

Publication number
CA2358438A1
CA2358438A1 CA002358438A CA2358438A CA2358438A1 CA 2358438 A1 CA2358438 A1 CA 2358438A1 CA 002358438 A CA002358438 A CA 002358438A CA 2358438 A CA2358438 A CA 2358438A CA 2358438 A1 CA2358438 A1 CA 2358438A1
Authority
CA
Canada
Prior art keywords
methyl
phenylamino
iodo
benzamide
difluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002358438A
Other languages
English (en)
Inventor
David Thomas Dudley
Judith Sebolt-Leopold
Alan Robert Saltiel
Annette Lynn Meyer
Stephen Joseph Gracheck
Alexander James Bridges
Peter Craig Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2358438A1 publication Critical patent/CA2358438A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Cette invention se rapporte à une méthode de prévention ou de traitement d'infections virales consistant à administrer à un patient nécessitant un tel traitement une quantité efficace d'un inhibiteur des kinases MEK, et notamment une phénylamine représentée par les formules (I) et (II).
CA002358438A 1999-01-07 1999-12-21 Methode antivirale utilisant des inhibiteurs de mek Abandoned CA2358438A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11502699P 1999-01-07 1999-01-07
US60/115,026 1999-01-07
PCT/US1999/030484 WO2000040237A1 (fr) 1999-01-07 1999-12-21 Methode antivirale utilisant des inhibiteurs de mek

Publications (1)

Publication Number Publication Date
CA2358438A1 true CA2358438A1 (fr) 2000-07-13

Family

ID=22358895

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002358438A Abandoned CA2358438A1 (fr) 1999-01-07 1999-12-21 Methode antivirale utilisant des inhibiteurs de mek

Country Status (8)

Country Link
EP (1) EP1140067A1 (fr)
JP (1) JP2002534381A (fr)
AU (1) AU2203800A (fr)
CA (1) CA2358438A1 (fr)
HU (1) HUP0104933A3 (fr)
IL (1) IL144103A0 (fr)
WO (1) WO2000040237A1 (fr)
ZA (1) ZA200104000B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050398A2 (fr) 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Derives de pyridinyl et de phenyle
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
EE05450B1 (et) * 2000-07-19 2011-08-15 Warner-Lambert Company 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine
EP1201765A3 (fr) * 2000-10-16 2003-08-27 Axxima Pharmaceuticals Aktiengesellschaft Kinases cellulaires impliqués dans l'infection par cytomégalovirus et leur inhibition
ATE345788T1 (de) * 2001-03-06 2006-12-15 Dorian Bevec Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
DE10138912A1 (de) * 2001-08-08 2003-02-27 Medinnova Ges Med Innovationen Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
PL401637A1 (pl) 2002-03-13 2013-05-27 Array Biopharma Inc. N3 alkilowane pochodne benzimidazolu jako inhibitory MEK
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
KR101013932B1 (ko) 2003-10-21 2011-02-14 워너-램버트 캄파니 엘엘씨 Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
WO2005051302A2 (fr) 2003-11-19 2005-06-09 Array Biopharma Inc. Inhibiteurs bicycliques de mek, et leurs procedes d'utilisation
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005051304A2 (fr) 2003-11-21 2005-06-09 Array Biopharma Inc. Inhibiteurs de la proteine kinase akt
ME01480B (fr) 2004-06-11 2014-04-20 Japan Tobacco Inc Dérivés de 5-amino-2,4,7-trioxo-3,4,7,8-tétrahydro-2h-pyrido'2,3-d! pyrimidine et composés apparentés pour le traitement du cancer
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
SE0401969D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
KR20080019236A (ko) 2005-05-18 2008-03-03 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
ATE493418T1 (de) 2006-07-06 2011-01-15 Array Biopharma Inc Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
BRPI0713555A2 (pt) 2006-07-06 2012-03-20 Array Biopharma, Inc. ciclopenta [d] pirimidinas como inibidores de akt protéina cinase
SI2054418T1 (sl) 2006-07-06 2012-02-29 Array Biopharma Inc Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
US7999006B2 (en) 2006-12-14 2011-08-16 Exelixis, Inc. Methods of using MEK inhibitors
CN101918373B (zh) 2007-07-05 2013-06-05 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR20150089099A (ko) 2007-07-05 2015-08-04 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
JP5346345B2 (ja) 2008-01-09 2013-11-20 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン類
WO2009089453A1 (fr) 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrimidyl cyclopentane hydroxylé en tant qu'inhibiteur de protéine kinase akt
JP5746630B2 (ja) 2008-11-10 2015-07-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換スルホンアミドフェノキシベンズアミド
WO2011047795A1 (fr) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Benzosulfonamides substitués
EP2491014A1 (fr) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Dérivés d'halogénophénoxybenzamide substitués
CA2777304A1 (fr) 2009-10-21 2011-04-28 Marion Hitchcock Benzosulfonamides substitues
US8993622B2 (en) 2010-06-11 2015-03-31 Eirium Ab Antiviral compounds
US9045429B2 (en) 2010-10-29 2015-06-02 Bayer Intellectual Property Gmbh Substituted phenoxypyridines
CN107233343A (zh) 2011-04-01 2017-10-10 基因泰克公司 Akt抑制剂化合物和化疗剂的组合以及使用方法
EP2694073B1 (fr) 2011-04-01 2018-08-08 Genentech, Inc. Combinaisons de inhibiteurs d'akt et mek pour le traitement du cancer
KR102174576B1 (ko) * 2012-10-08 2020-11-06 아트리바 테라퓨틱스 게엠베하 바이러스 질환 치료에서의 ｍｅｋ 억제제
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
CA2923835C (fr) 2013-09-11 2022-11-29 The Administrators Of The Tulane Educational Fund Nouveaux amides anthraniliques et utilisation de ces derniers
EA202090693A1 (ru) * 2017-10-17 2020-10-19 Атрива Терапьютикс Гмбх Новый ингибитор mek для лечения вирусных и бактериальных инфекций

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420338B1 (en) * 1997-06-13 2002-07-16 New York University Medical Center Inhibition of the Src kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma
PT993439E (pt) * 1997-07-01 2004-12-31 Warner Lambert Co Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek
NZ501277A (en) * 1997-07-01 2002-12-20 Warner Lambert Co -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors

Also Published As

Publication number Publication date
EP1140067A1 (fr) 2001-10-10
IL144103A0 (en) 2002-05-23
WO2000040237A1 (fr) 2000-07-13
ZA200104000B (en) 2002-08-16
HUP0104933A3 (en) 2003-12-29
AU2203800A (en) 2000-07-24
JP2002534381A (ja) 2002-10-15
HUP0104933A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
CA2358438A1 (fr) Methode antivirale utilisant des inhibiteurs de mek
AU776788C (en) Treatment of arthritis with MEK inhibitors
US6696440B1 (en) Treatment of asthma with MEK inhibitors
US6251943B1 (en) Method of treating or preventing septic shock by administering a MEK inhibitor
EP1140291B1 (fr) Chimiotherapie utilisant un inhibiteur de la mitose avec un inhibiteur mek
AU756586C (en) 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6972298B2 (en) Method of treating or inhibiting neutrophil chemotaxis by administering a MEK inhibitor
US6310060B1 (en) 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
AU2180500A (en) Use of a mek inhibitor for preventing transplant rejection
US20040171632A1 (en) Combination chemotherapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued